BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.
To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found that the variant genotypes of 6007C > T polymorphisms significantly associated with the chemotherapy response. The 6007CC genotype carriers had a higher chance to be responder to chemotherapy (adjusted odd ratio = 2.77; 95% CI: 1.83-4.18; adjusted < 0.001). The 6007C > T polymorphisms and BMP-4 expression also affect the prognosis of NSCLC. Patients with high BMP-4 expression had a significantly higher chance to be resistant to chemotherapy than those with low BMP-4 expression (OR = 2.81; 95% CI: 1.23-6.44; P = 0.01). The hazard ratio (HR) for 6007TT was 2.37 times higher than 6007CC (P = 0.003). In summary, the 6007C > T polymorphism of BMP-4 gene and BMP-4 tissue expression may be used as potential predictor for the chemotherapy response and prognosis of advanced NSCLC.
Department of Oncology, Third Affiliated Hospital of Harbin Medical University, 150 Ha Ping Road, Nangang District, Harbin, Heilongjiang Province 150086, China.
Sun
S
Xian
Department of Cardiac Surgery, Second Affiliated Hospital of Harbin Medical University, 246 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China.
Lang
L
Jilu
Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China.
Tian
T
Zhennan
Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China.
Zhou
Z
Yang
Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China.
Hu
H
Yang
Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China.
Geng
0000-0003-0351-3998
G
Jingshu
Laboratory of Medical Genetics, Harbin Medical University, 194 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China.
Fu
F
Songbin
D000368:Aged; D055415:Bone Morphogenetic Protein 4 / Q000096:biosynthesis / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010984:Platinum / Q000008:administration & dosage; D011379:Prognosis
C525809:BMP4 protein, human; D055415:Bone Morphogenetic Protein 4; D010984:Platinum